Rheumatology
Wilburn J, McKenna SP, Twiss J, Rouse M, Korkosz M, Jancovic R, Nemec P, Pacheco-Tena CF, Saraux A, Westhovens R, Durez P, Martin M, Tammaru M. Further international adaptation and validation of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire. Rheumatol Int. 2015 Apr;35(4):669-75. doi: 10.1007/s00296-014-3138-4
Graham JE, Rouse M, Twiss J, McKenna SP, Vidalis AA. Greek adaptation and validation of the Ankylosing Spondylitis Quality of Life (ASQoL) measure. Hippokratia. 2015;19(2):119-24.
Wu JJ, Rowan CG, Bebchuk JD, Anthony MS. Total cholesterol, lipoprotein, and triglyceride levels in tumor necrosis factor inhibitor-treated patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis. Int J Dermatol. 2015 Oct;54(10):e442-5. doi: 10.1111/ijd.12921
Abstract not available at this time.
Carlson AM, Stockwell-Morris L, Perfetto EM, Appel AM, Gilsenan AW. Quality of sleep in patients with osteoarthritis treated with extended-release and conventional etodolac. J Am Pharm Assoc. 1998 Jan;38(1):31-6. doi: 10.1016/S1086-5802(16)30297-2
Objective: To examine patient-perceived quality of sleep related to osteoarthritis (OA) of the knee before and after treatment with etodolac (Lodine and Lodine XL-Wyeth-Ayerst Laboratories), a nonsteroidal anti-inflammatory drug (NSAID).
Gilsenan AW, Morris LS, Carlson AM. Association between quality of sleep and NSAID use for osteoarthritis in older patients. Presented at the American Society of Consultant Pharmacists National Meeting; 1996. Nashville, TN.
Abstract not available at this time.
Accortt N, Anthony MS, Schenfeld J, Wheeling T, Hassebroek A, O'Malley CD, Sprafka M. Incidence and prevalence of myasthenia gravis in rheumatoid arthritis patients with and without treatment compared with the general population. Poster presented at the 2014 ACR/ARHP Annual Meeting; November 2014. Boston, MA. [abstract] Arthritis Rheumatol. 2014 Oct; 66(Suppl 1):S895.
Background/Purpose: There is a dearth of information on the incidence rate of myasthenia gravis (MG) in the US and specifically among rheumatoid arthritis (RA) patients. RA patients have been shown to be at risk for other autoimmune diseases so we sought to describe the rate of MG among RA patients, with and without treatment.
Launois R, Le Moine JG, Huynh MT, Boissier MC. Efficacité et tolérance des traitements de la polyarthrite rhumatoïde étudiés par méta-analyse hiérarchique bayésienne: combinaison simultanée des résultats relevés dans les essais randomisés et les études observationnelles avec groupe controle. Presented at the French Society of Rheumatology 23rd Annual Congress; November 28, 2010. Paris, France.
Abstract not available at this time.
Launois R, Le Moine JG, Huynh MT, Boissier MC. Analyse de l'impact budgétaire de la prise en charge de la polyarthrite rhumatoïde en 1ère, 2ème et 3ème ligne de traitement, après échec d'un traitement de fond. Presented at the French Society of Rheumatology 24th Annual Congress; December 11, 2011. Paris, France.
Abstract not available at this time.
Le Moine JG, Launois R. Mixed treatment comparison, cost-effectiveness analysis and budget impact model in the treatment of rheumatoid arthritis after failure of conventional DMARD therapy using comprehensive Bayesian decision analytical modelling. Presented at the 3rd Joint CES/HESG Workshop; January 11, 2012. Aix-en-Provence, France.
Abstract not available at this time.